Dacryocystography

DEMOREST, BYRON H.

doi:10.1001/archopht.1955.00930020416013

Cited by 38 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, although epiphora was referred in 50.0% of cases at T1 (n = 16/32) and in 31.25% (n = 10/32) at T2, Munk scores 3 and 4 were reported in 93.75% (n = 30/32) of eyes at T0, while only in 15.63% (n = 5/32) and 9.38% (n = 3/32) in T1 and T2, respectively (Table 2). This occurrence, in the presence of anatomical patency of the lower lacrimal system, may indeed be explained by some anti-glaucoma drops' effects on the upper system and/or by the so called "functional block" [8].…”

Section: Discussionmentioning

confidence: 97%

“…Most frequently, the site of obstruction is the junction between the lacrimal sac and the nasolacrimal duct [7]. Nevertheless, in many cases patients experience lacrimal drainage dysfunction in the presence of anatomical patency: to define this concept, in 1955 Demorest and Milder introduced the expression "functional block" [8]. The association between an NLDO and a U-NLDO, or with a functional block, represents a major cause of DCR failure and persisting epiphora, thus enhancing the relevance of adequate patient selection as a key point in obtaining a positive surgical outcome.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes of Endoscopic Endonasal Dacryocystorhinostomy in Glaucoma Patients

Pace,

Giombi,

Muci

et al. 2024

JPM

View full text Add to dashboard Cite

Background: Anti-glaucoma eye drops have been investigated due to their production of fibrotic changes on the conjunctival surface, undermining the functioning of the upper lacrimal drainage system. We aimed to assess whether these effects may impair the effectiveness of endoscopic endonasal dacryocystorhinostomy (EE-DCR). Methods: This is a single-center observational retrospective study on EE-DCR via a posterior approach. Resolution of epiphora and dacryocystitis were analyzed after 1 (T1) and 6-months (T2) from surgery. Surgical success was defined as anatomical (patency at irrigation, no recurring dacryocystitis) or complete (zeroing of Munk score). Results: Twenty patients (32 sides) were enrolled. Preoperatively, 93.75% (n = 30/32) presented severe (Munk 3–4) epiphora and 68.75% (n = 22/32) recurrent dacryocystitis. At T1, 50.0% (n = 16/32) were referred with residual epiphora (Munk ≥ 1) and 18.75% (n = 6/32) dacryocystitis. At T2, 31.25% (n = 10/32) still complained of epiphora (Munk ≥ 1) and 6.25% (n = 2/32) dacryocystitis. Difference of outcomes at aggregate and paired timepoints (except for T1 versus T2) resulted in statistical significance (p < 0.05). At T2, 22 (68.75%) complete, 8 (25.0%) anatomical successes and 2 (6.25%) surgical failures were observed. Conclusions: Despite the chronic uptake of anti-glaucoma eye drops, EE-DCR guaranteed high rates of clinical relief from epiphora and remarkable decreases in the rates of recurrent dacryocystitis.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Outcomes of Endoscopic Endonasal Dacryocystorhinostomy in Glaucoma Patients

Pace,

Giombi,

Muci

et al. 2024

JPM

View full text Add to dashboard Cite

show abstract

“…In fact, although epiphora was referred in 51.7% of cases at T1 (n = 15/29) and in 31.2% (n = 9/29) at T2, Munk scores 3 and 4 were reported in 93.1% of eyes at T0, while only in 20.7% and 10.4% in T1 and T2 respectively. This occurrence, in the presence of anatomical patency of the lower lacrimal system, may indeed be explained by some anti-glaucoma drops' effects on the upper system and/or by the so called "functional block" [9].…”

Section: Discussionmentioning

confidence: 97%

“…Nevertheless, in many cases patients experience lacrimal drainage dysfunction in the presence of anatomical patency: to de ne this concept in 1955 Demorest and Milder introduced the expression "functional block" [9]. The association between a NLDO with a U-LDSO or with a functional block represents a major cause of DCR failure and persisting epiphora, thus enhancing the relevance of an adequate patient's selection as a key point to obtain a good surgical outcome.…”

Section: Introductionmentioning

confidence: 99%

Endoscopic endonasal dacryocystorhinostomy: is assuming topical anti-glaucoma medications a contraindication?

Pace

Giombi

Muci

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose Topical anti-glaucoma medications have been investigated on producing fibrotic changes on the conjunctival surface, undermining the functioning of the upper lacrimal drainage system. The aim of the study was to assess whether these effects may impair the effectiveness of dacryocystorhinostomy (DCR) in patients affected by both glaucoma and nasolacrimal duct obstructions (NLDO).Methods Single-center observational retrospective study on endoscopic endonasal-DCR (EE-DCR) via posterior approach. Consecutive patients were enrolled in 2020–2023 and evaluated with proper questionnaires; resolution of epiphora and dacryocystitis were analyzed after 1 (T1) and 6-months (T2) from surgery. Surgical success was defined as anatomical (patency at irrigation, no recurring dacryocystitis) or complete (zeroing of Munk score)Results 17 patients (29 operated sides) were enrolled. Preoperatively, 92.1% (n = 27/29) presented severe (Munk 3–4) epiphora and 69.0% (n = 20/29) recurrent dacryocystitis. At T1, 51.72% (n = 15/29) referred residual epiphora (Munk ≥ 1) and 17.20% (n = 5/29) dacryocystitis. At T2, 34.5% (n = 10/29) still complained epiphora (Munk ≥ 1) and 6.9% (n = 2/29) symptoms of dacryocystitis. Difference of outcomes at aggregate and paired timepoints (except for T1 versus T2) resulted statistically significant (p < 0.05). At T2, 20 (69.0%) complete, 7 (24.2%) anatomical successes and 2 surgical failures (6.8%) were observed.Conclusions EE-DCR in patients suffering from NLDO despite the chronic uptake of anti-glaucoma topical medications guaranteed high rates of clinical relief from epiphora and remarkable decreases in the rates of recurrent dacryocystitis, appearing as a reasonable therapeutical strategy to improve disease-related quality of life.

show abstract

Lids, Lacrimal Apparatus, and Conjunctiva

Beard¹

1959

Archives of Ophthalmology

View full text Add to dashboard Cite

Dacryocystography

Cited by 38 publications

References 3 publications

Outcomes of Endoscopic Endonasal Dacryocystorhinostomy in Glaucoma Patients

Outcomes of Endoscopic Endonasal Dacryocystorhinostomy in Glaucoma Patients

Endoscopic endonasal dacryocystorhinostomy: is assuming topical anti-glaucoma medications a contraindication?

Lids, Lacrimal Apparatus, and Conjunctiva

Contact Info

Product

Resources

About